Form 4: Castle Biosciences CEO Derek Maetzold Executes Stock Sales Under 10b5-1 Plan

Derek Maetzold, CEO of Castle Biosciences, sold shares of common stock through a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 9, 2024, Derek J Maetzold, the President and CEO of Castle Biosciences, sold shares of the company's common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 24, 2024.
• Maetzold sold 996 shares directly at a price of $29.457 per share.
• He also sold shares held indirectly through various trusts, including The Maetzold Descendants 2020 Trust (512 shares), Derek Maetzold 2020 Irrevocable Trust (478 shares), and several Maetzold 2018 Remainder Trusts (150 shares each).
• Following these transactions, Maetzold directly owns 98,576 shares.
• He also indirectly owns shares through several trusts, including 122,866 shares via DJM Grantor Retained Annuity Trust No. 5 and 26,134 shares via DJM Grantor Retained Annuity Trust No. 6.
• The sales were executed at prices ranging from $29.190 to $29.705.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock sales under a pre-existing plan. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

Insider trading activity is always closely watched by investors as it can provide signals, though often noisy, about management's view of the company's prospects. Sales under a pre-arranged 10b5-1 plan are generally less concerning as they are planned in advance.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates